4//SEC Filing
Bartels Ursula B 4
Accession 0001179110-09-012860
CIK 0000874255other
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:02 PM ET
Size
17.6 KB
Accession
0001179110-09-012860
Insider Transaction Report
Form 4
MEDAREX INCMEDX
Bartels Ursula B
Sr. V.P., Gen. Counsel & Sec.
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−200,000$3,200,000→ 0 totalExercise: $12.09Exp: 2017-10-30→ Common Stock (200,000 underlying) - Disposition to Issuer
Restricted Stock Units
2009-09-01$16.00/sh−54,455$871,280→ 0 total→ Common Stock (54,455 underlying) - Disposition to Issuer
Restricted Stock Units
2009-09-01$16.00/sh−10,400$166,400→ 0 total→ Common Stock (10,400 underlying) - Disposition to Issuer
Restricted Stock Units
2009-09-01$16.00/sh−31,200$499,200→ 0 total→ Common Stock (31,200 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−31,200$499,200→ 0 totalExercise: $9.07Exp: 2018-03-02→ Common Stock (31,200 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−93,600$1,497,600→ 0 totalExercise: $3.72Exp: 2019-03-04→ Common Stock (93,600 underlying)
Footnotes (10)
- [F1]This option was canceled in the merger in exchange for a cash payment of $783,000.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F10]Receipt of the restricted stock units was deferred until March 13, 2012.
- [F2]This option was canceled in the merger in exchange for a cash payment of $216,372.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F3]This option was canceled in the merger in exchange for a cash payment of $1,497,600.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F4]Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
- [F5]This restricted stock unit was canceled in the merger in exchange for a cash payment of $166,400.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F6]This restricted stock unit was canceled in the merger in exchange for a cash payment of $499,200.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F7]This restricted stock unit was canceled in the merger in exchange for a cash payment of $871,280.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F8]Receipt of the restricted stock units was deferred until March 3, 2014.
- [F9]Receipt of the restricted stock units was deferred until March 5, 2013.
Documents
Issuer
MEDAREX INC
CIK 0000874255
Entity typeother
Related Parties
1- filerCIK 0001300250
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 4:02 PM ET
- Size
- 17.6 KB